Piel最新文献_第6页

¿Es halo nevus un fenómeno benigno? Revisión de la literatura 光环痣是良性现象吗？文学评论

Piel Pub Date : 2026-10-01 Epub Date: 2026-06-08 DOI: 10.1016/j.piel.2026.02.021

Silvia Aristizábal, Sara Correa, Sneider Torres

{"title":"¿Es halo nevus un fenómeno benigno? Revisión de la literatura","authors":"Silvia Aristizábal, Sara Correa, Sneider Torres","doi":"10.1016/j.piel.2026.02.021","DOIUrl":"10.1016/j.piel.2026.02.021","url":null,"abstract":"<div><div>Halo nevus represents a relevant diagnostic challenge in dermatology due to its clinical, dermoscopic, and histopathological similarity to regressing melanoma. With a prevalence of 1% in the general population, it typically presents during adolescence and is benign in this age group, while in adults it requires close surveillance. The pathophysiology involves an immune response mediated by CD8+T lymphocytes against melanocytic cells, following characteristic evolutionary stages. Clinical presentation varies by age, with symmetric halos predominating in patients under 15 years versus irregular patterns in adults. The critical differential diagnosis is with regressing melanoma, distinguished by specific clinical and histopathological characteristics. Management is conservative in children and adolescents, while in adults individualized evaluation is required. Multiple eruptive halo nevi in adults may present paraneoplastic risk, warranting oncological evaluation. Biopsy is indicated in adults over 40 years with de novo lesions or atypical features. The prognosis is excellent in pediatric populations and requires differentiated follow-up in adults.</div></div>","PeriodicalId":20182,"journal":{"name":"Piel","volume":"41 8","pages":"Pages 724-731"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149095663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experiencia en vida real con pembrolizumab neoadyuvante en melanoma estadio III: serie en un hospital de tercer nivel en España 西班牙三级医院新佐剂派姆单抗治疗黑色素瘤III期的实际经验：系列

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-18 DOI: 10.1016/j.piel.2025.12.008

Andrea Sánchez Moreno, Isabel Villegas Romero, David Jiménez Gallo, Mario Linares Barrios

{"title":"Experiencia en vida real con pembrolizumab neoadyuvante en melanoma estadio III: serie en un hospital de tercer nivel en España","authors":"Andrea Sánchez Moreno, Isabel Villegas Romero, David Jiménez Gallo, Mario Linares Barrios","doi":"10.1016/j.piel.2025.12.008","DOIUrl":"10.1016/j.piel.2025.12.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Neoadjuvant pembrolizumab has been shown to improve relapse-free survival (RFS) in stage III melanoma with clinically detectable nodal disease. We report our single-centre experience in a Spanish Tertiary Referral Center.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective, descriptive, single-centre study of patients with stage III melanoma and clinically detectable nodal involvement treated with 1–3 cycles of neoadjuvant pembrolizumab (200 mg every 3 weeks) between July 2020 and April 2025. Clinical and molecular characteristics, histopathological response, RFS, overall survival (OS), adjuvant treatment and immune-related toxicities were recorded.</div></div><div><h3>Results</h3><div>Six patients were included, with a median age of 46 years; 83% harbored a BRAF V600 mutation. According to the AJCC 8th edition, 66% were stage IIIC and 33% stage IIID. Histopathological assessment showed a 25% pathological complete response (pCR), 25% near-complete response (n-pCR) and 50% pathological partial response (pPR). All patients achieving at least pPR remain free of progression, with RFS and OS rates of 100% after a median follow-up of 25 months, whereas non-responders had a median RFS of 1.5 months and OS of 8.5 months. Immune-related toxicity occurred in 17% of patients, without additional severe adverse events.</div></div><div><h3>Conclusions</h3><div>Neoadjuvant pembrolizumab for stage III melanoma with clinically detectable nodal disease is associated with high rates of pathological response and prolonged RFS and OS in responders, with an acceptable safety profile. Our findings support its incorporation as a minimum standard strategy in this patient population.</div></div>","PeriodicalId":20182,"journal":{"name":"Piel","volume":"41 6","pages":"Pages 497-502"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148202415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hidradenitis supurativa paradójica inducida por infliximab en un paciente con colitis ulcerosa 溃疡性结肠炎患者因infliximab引起的异质性化脓性水腺炎

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-18 DOI: 10.1016/j.piel.2025.12.003

Josefina Gazmuri , Sofía Gómez-Barris , María Fernanda Echeverría , Colomba Cofré , Yalda Lucero , Marianne Kolbach

引用次数: 0

Tétrada de obstrucción folicular: revisión de 4 enfermedades o un mismo diagnóstico? 滤泡阻塞检查：4种疾病的复查还是相同的诊断？

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-23 DOI: 10.1016/j.piel.2025.12.009

Juan Raúl Castro Ayarza , Sebastián Andres Ortiz Cabrales , Samanda Juliana Suárez García , Claudia González

{"title":"Tétrada de obstrucción folicular: revisión de 4 enfermedades o un mismo diagnóstico?","authors":"Juan Raúl Castro Ayarza , Sebastián Andres Ortiz Cabrales , Samanda Juliana Suárez García , Claudia González","doi":"10.1016/j.piel.2025.12.009","DOIUrl":"10.1016/j.piel.2025.12.009","url":null,"abstract":"<div><div>The follicular occlusion tetrad (FOT) encompasses four chronic dermatologic disorders: hidradenitis suppurativa, acne conglobata, dissecting cellulitis of the scalp, and pilonidal disease, which share a pathophysiology based on follicular occlusion and secondary inflammation. The aim of this review was to analyze the available literature to explore the hypothesis that these conditions represent clinical variants of the same pathophysiological process. A manual search of databases was conducted, including studies published between 2000 and 2024. The evidence suggests that the entities within the FOT share a common initiating event: abnormal keratinization and follicular occlusion, which trigger an intense inflammatory response involving the immune system. Each disorder presents clinical, epidemiological, and therapeutic particularities, although there is considerable overlap in their management. The coexistence of two or more entities in the same patient is frequent, and the shared response to certain treatments reinforces the hypothesis of a common etiology. Recognition of this interrelationship is essential for a comprehensive diagnostic and therapeutic approach. Despite recent advances, further studies are needed to establish standardized guidelines and determine whether the FOT should be regarded as a single clinical spectrum rather than four distinct entities.</div></div>","PeriodicalId":20182,"journal":{"name":"Piel","volume":"41 6","pages":"Pages 521-528"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148202364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Triple alopecia cicatricial asociada a melanoma cutáneo: coexistencia de liquen plano pilaris, foliculitis decalvante y foliculitis queloidea 与皮肤黑色素瘤相关的瘢痕性三重脱发：毛细血管扁平苔藓、脱毛性毛囊炎和毛囊毛囊炎共存

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-20 DOI: 10.1016/j.piel.2026.01.006

Ismael Erazo Astudillo , Robinson Guerrero Araya , Francisco Erazo Astudillo , Gonzalo Vera Santis

引用次数: 0

Nódulo acral doloroso 疼痛的骶结节

Piel Pub Date : 2026-06-01 Epub Date: 2026-04-07 DOI: 10.1016/j.piel.2025.10.021

Laura García Blanco, Liliana Eugenia Muñoz, Yaisa Valeria Diaz

引用次数: 0

Creatina y exantema intertriginoso y flexural simétrico relacionado con fármacos: ampliando el espectro de desencadenantes no prescritos 肌酸和与药物相关的肌间质和对称屈肌皮疹：扩大非处方触发器的范围

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-14 DOI: 10.1016/j.piel.2025.11.013

Juan Camilo Saldarriaga-Giraldo , Carolina Velásquez-Botero , Aura Sofía Arteaga-Calderón , Ana María Mejía-Giraldo

引用次数: 0

Melanoma lentiginoso acral: perfil clínico y resultados quirúrgicos en una serie de un hospital de tercer nivel 肢端黑色素瘤：一系列三级医院的临床概况和手术结果

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-17 DOI: 10.1016/j.piel.2025.12.004

Mar Rodríguez-Troncoso, María Zulaika-Lloret, Francisco Manuel Almazán-Fernández, Ricardo Ruiz Villaverde

引用次数: 0

Perdiendo la cabeza en el diagnóstico diferencial: cuando la arteritis de células gigantes se manifiesta también en el cuero cabelludo 在鉴别诊断中失去头部：当巨细胞动脉炎也出现在头皮上时

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-20 DOI: 10.1016/j.piel.2025.11.016

Lucía Martínez Rozas , María Castellanos González , Francisco Javier Sanz Carrio , José Luis López Estebaranz

引用次数: 0

Melanoma de células balonizadas

Piel Pub Date : 2026-06-01 Epub Date: 2026-03-14 DOI: 10.1016/j.piel.2025.11.017

Camila Gacitúa Muñoz , Nicolás Opazo Rivera , María Fernanda Flores Alvarado , Ángelo Baeza Sprohnle

引用次数: 0